Drug Trial Radar · NCT04947956
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Sep 1, 2021
Primary completion
Sep 1, 2023
Study completion Sep 1, 2025
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 1, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
Primary liver cancer is the second most common cause of cancer death in China, and hepatocellular carcinoma (HCC) represents more than 80% of liver cancer cases. The majority of HCC cases present at an advanced stage, and are thus not amenable to surgery. Immunotherapies, including PD-1 and PD-L1 inhibitors, alone or combined with other regimens, have shown encouraging clinical activity in unresectable HCC. Camrelizumab, a humanised monoclonal antibody against PD-1, has been shown to block the binding of PD-1 to PD-L1 and consequently inhibit the immune escape of tumour cells, which has been approved for the second-line treatment of advanced HCC. This observational study aims to evaluate the safety and efficacy of camrelizumab in Chinese unresectable HCC in the real world.
Conditions
- Unresectable Hepatocellular Carcinoma
Interventions
CamrelizumabDrug
The camrelizumab-based treatment will be determined by the investigator.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent adverse events (TEAE)Time frame: Up to ~2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.